You are here: Industry Insights > daratumumab

News List

FDA Approves Belumosudil for Graft-Versus-Host Disease americanpharmaceuticalreview
July 20, 2021
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including ...
SC formulation of DARZALEX combination delivers deep and rapid haematologic responses and improved clinical outcomes in newly diagnosed light chain amyloidosis pharmaceutical-business-review
June 18, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the first randomised Phase 3 study investigating the subcutaneous (SC) formulation of DARZALEX (daratumumab) in the treatment of patients ...
Janssen gets EC approval for subcutaneous use of daratumumab pharmaceutical-business-review
June 09, 2020
Johnson & Johnson’s Janssen Pharmaceutical has secured approval from the European Commission for the subcutaneous formulation of Darzalex (daratumumab) for the treatment of multiple myeloma in adult patients.
Daratumumab Cuts Risk for Progression in Multiple Myeloma drugs
May 30, 2019
Daratumumab Cuts Risk for Progression in Multiple Myeloma.
Daratumumab Cuts Risk for Progression in Multiple Myeloma drugs
May 30, 2019
Daratumumab Cuts Risk for Progression in Multiple Myeloma.
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation firstwordpharma
March 26, 2019
Healthcare professionals including haematologists, oncologists, oncology nurses, oncology pharmacists, and other healthcare ……
Janssen unveils new data backing wider use of Darzalex pharmatimes
December 06, 2018
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Darzalex combo wins nod for newly diagnosed multiple myeloma pharmatimes
July 09, 2018
Janssen/Genmab's Darzalex has become the first monoclonal antibody to be approved in the US to treat patients newly diagnosed with multiple myeloma.
SMC approves daratumumab for myeloma patients in Scotland pharmaceufical-technology
October 12, 2017
The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.
Phase II Lymphoma study of Daratumumab will not continue to stage 2 europeanpharmaceuticalreview
April 05, 2017
Genmab and Janssen Biotech have decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL).